



Loss of incretin effect contributes to post-prandial hyperglycaemia in cystic fibrosis related diabetes.
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	This study is the first to measure the incretin effect in people with cystic fibrosis.
	In people with cystic fibrosis, but not diabetes, the incretin effect is similar to healthy controls.
	The incretin effect is lost in people with cystic fibrosis related diabetes despite adequate secretion of  GLP-1 and GIP





Cystic fibrosis related diabetes (CFRD), characterised by post-prandial hyperglycaemia, is associated with deleterious clinical outcomes. In health, the incretin hormones are a major determinant of post-prandial hyperglycaemia and incretin-targeted drugs have recently become available. However, little is known about the role of the incretin hormones in CFRD. We therefore investigated the incretin axis in people with CF.
Materials & Methods
Adults with CFRD, CF but not diabetes and healthy controls underwent an oral glucose tolerance test (OGTT) and then a closely matched isoglycaemic intravenous glucose infusion (IIGI). On each occasion glucose, insulin, C-peptide, total and active Glucagon-Like Peptide-1 (GLP1) and Gastric Inhibitory Polypeptide (GIP) responses were recorded and the incremental area under curves were calculated  for 60 (AUC60) and 240 minutes (AUC240).
Results
Five adults with CFRD, 6 with CF but not diabetes (CFnD) and 6 healthy controls (HC) matched for age and body mass index completed the study. Glucose during OGTT closely matched those during IIGI.  The calculated incretin effect was similar between HC and CFnD (28.2% and 29.1% respectively) but was lost in CFRD (-6.1%, comparison vs. healthy controls -6.1% vs. 28.2%, p=0.03). No hyposecretion of GLP-1 or GIP was observed, conversely incremental AUC60 for total GLP-1 was significantly higher in the CFRD group compared to controls (1070.4(254.7) vs. 694.97 (308.1), p=0.03)
Conclusion
We found the incretin effect is lost in CFRD despite adequate secretion of the incretin hormones. These data support the concept that reduced incretin hormone insulinotropic activity contributes significantly to post-prandial hyperglycaemia in CFRD.
ClinicalTrials.gov Identifier: NCT01975259
Background: 
The gut-derived insulinotropic incretin hormones Glucagon-Like Peptide-1 (GLP1) and Gastric Inhibitory Polypeptide (GIP) released after oral nutrient ingestion account for up to two-thirds of the subsequent insulin response, termed the “incretin effect”, and are a major determinant of the regulation of post-prandial glucose homeostasis. [1] Cystic fibrosis related diabetes (CFRD), characterised by postprandial hyperglycaemia with fasting normoglycaemia,  ADDIN EN.CITE [2, 3] occurs in up to 50% of people with CF as they age, and is associated with accelerated pulmonary function decline, poor nutritional status and excess mortality. [3] Treatment with insulin can be associated with improved outcomes, [4] however hypoglycaemias are also common in people with CF regardless of diabetic status and achieving optimal glycaemic control after insulin initiation can be challenging.  ADDIN EN.CITE [5, 6]
 An understanding of the mechanisms underpinning glucose homeostasis in CF is therefore important and recently, interest in the incretin hormones has been fuelled by the development of incretin axis targeted therapies that have become available for the management of type 2 diabetes mellitus (T2DM).  ADDIN EN.CITE [7-9] Despite this, few studies have investigated the incretin axis in people with CF, and the “incretin effect” in this population is unknown. An understanding of the incretin effect and its role in glucose homeostasis in people with CF is needed before new incretin therapies can be considered for people with CFRD.
We used oral glucose challenges and matched intravenous isoglycaemic glucose infusion clamps (IIGI) to investigate the incretin effect in CF people with and without CFRD, comparing them with healthy controls [ClinicalTrials.gov Identifier: NCT01975259].
Methods:
Study Population
We recruited people with CF from our large regional adult centre, both with CFRD and without CFRD (CFnD), along with healthy non-diabetic controls (HC) from the general population, age- and BMI- matched to the CF groups. All subjects with CF had a diagnosis confirmed by two known pathogenic CFTR variants. Healthy controls were confirmed as non-diabetic by a standard 75 g 2-hour oral glucose tolerance test (OGTT) carried out within the preceding 3 months, and additionally CF subjects underwent continuous glucose monitoring (CGM) over a 3–5 day period within the same time frame. CF was confirmed by two pathogenic Cystic fibrosis transmembrane regulator protein (CFTR) mutations on genotyping, or a positive sweat test and clinical features in keeping with CF. CFRD was defined as need for on-going insulin therapy and confirmed by a 2 hour OGTT blood glucose >11.1mmol/L or continuous glucose monitor (CGM) with >4.5% time >7.8mmol/L. [10] The CFnD group was defined as no history of CFRD and a normal OGTT, or if evidence of impaired glucose tolerance on OGTT, <4.5% time spent >7.8mmol/L on CGM. 
Study procedures
After informed consent, subjects attended two visits at least 48 hours apart, abstained from vigorous exercise for 48 hours prior to each visit and followed their usual diet during this period. Given the incretin effect can be potentiated by bile acid sequestrants [11], those with CF omitted ursodeoxycholic acid for four weeks and any other regular medications, other than pancreatic replacement therapy, for 24 hours prior to each visit. Those with CFRD suspended long-acting insulin for 48 hours prior to each visit. 
On each visit, subjects were studied in the morning following an overnight 10-hour fast. A cannula was inserted in the cubital vein for collection of blood samples. Venous blood was arterialised by warming the arm between blood draws. On the first visit, subjects underwent a 4-hr 50g OGTT (Polycal, Nutricia, UK). On the second visit, a 4-hr matched isoglycaemic intravenous glucose infusion (IIGI) was carried out [glucose 20% at variable rate] to closely match glucose values obtained at the first visit OGTT. 

At each visit, blood was sampled at -15, 0 and 15, 30, 45, 60, 90, 120, 180 and 240 minutes. Two aliquots of blood, one of which contained a Dipeptidyl peptidase 4 (DPP4) inhibitor (Sigma-Aldrich Ltd, UK) were both taken on ice and immediately centrifuged at 4000 rpm for 10 minutes at 4 degrees.  Aliquots were stored at -80o C until analysis. 
Laboratory analyses
Plasma glucose was measured in duplicate by glucose oxidase method using the automated YSI 2300 analyser (YSI 2300; YSI Inc., Yellow Springs, USA). Insulin, C-peptide, Total GLP-1 (tGLP-1), active GLP-1 (aGLP-1) and total GIP were measured using ELISA assays (EMD Millipore, Missouri, USA).
Data analyses
Area under curve (AUC) was calculated for 60 minutes (AUC60) and 240 minutes (AUC240) using the trapezoidal rule and incremental AUC was obtained by deducting the area below baseline from the total AUC. The incretin effect was calculated as the difference between total insulin secretion (TIS) response to OGTT and IIGI, expressed as a percentage of the TIS in OGTT [Incretin effect = (TISOGTT – TISIIGI )/ TISOGTT], as previously described. [7]  
Statistical methods: 
All statistical analyses were performed in R (R Foundation for Statistical Computing, Vienna, Austria). Normality of parameter distribution was tested by the Shapiro-Wilk test. Parameters are expressed as mean (SD) or median [inter-quartile range] unless otherwise stated. Differences within the group at each time point were compared using paired t-tests for normally distributed data and Wilcoxon signed ranks for non-normally distributed data. Differences between groups were compared using repeated measures ANOVA with the post-hoc independent t-test for normally distributed data and the Kruskall-Wallace test with the post-hoc Mann-Whitney U test for non-normally distributed data.  A p-value of <0.05 was considered statistically significant and unadjusted p-values are presented throughout.
Results:
The study population comprised six healthy controls, six (CFnD) and five CFRD (demographic and clinical characteristics in Table 1). Subjects were well matched for age and BMI (Table 1), but as expected those with CFRD had poorer lung function than those with CFnD (median [IQR] FEV1 3.34L [2.72-3.66] vs. 2.48 L [1.76-2.68], p=0.03). 
Glucose: 
Glucose profiles during the IIGI closely matched those during OGTT (Figure 1) and there were no within-subject differences between either AUC60OGTT and AUC60IIGI or AUC240OGTT and AUC240IIGI (Table 2). OGTT and IIGI were tolerated well with only one hypoglycaemia (3.2mmol/L) noted in a subject with CFnD who was asymptomatic. The mean (SD) intravenous glucose necessary to achieve isoglycaemia was similar across all groups (Controls: 25.1g (9.8); CFnD: 32.7g (11.5); CFRD 27.1g (10.2), p=NS). During OGTT, the CFRD group exhibited significantly greater glycaemic excursions compared to CFnD (peak glucose 12.3 (2.3) mmol/L vs. 8.9 (1.5) mmol/L, p=0.01) and also healthy controls (peak glucose 12.3 (2.3) mmol/L vs. 8.5 (1.5) mmol/L, p=0.02). Similarly, glucose AUC240OGTT was greater in CFRD than both CFnD and HC (Table 2). 
Insulin and C-Peptide:
Fasting plasma insulin was significantly higher in the HC group compared to both the CFRD and CFnD groups (HC: 6.2 mU/ml vs. CFRD: 2.6 mU/ml, p<0.01; CFnD: 3.2 mU/ml, p=0.04). Time courses for plasma insulin and C-peptide are shown in Figure 1 and incremental AUCs and peak values for insulin and C-peptide are presented in Table 2. The AUC60OGTT was significantly lower in the CFRD group compared to HC for both insulin (mean [SD] 669.5 [241.7] mU/ml.min vs. 1397.2 [634.26] mU/ml.min, p=0.02) and C-peptide (56.2 [9.9] mU/ml.min vs. 114.9 [51.6] mU/ml.min, p=0.02), see Table 1. The median [IQR] 30 minute ratio between glucose and C-peptide, a predictor of beta-cell area, was significantly lower in the CFRD group (0.20 [0.03 to 0.22] compared to HC (0.39 [0.38 to 0.42], p=0.04).
Incretin effect
The incretin effect was lost in CFRD where the insulin secretion was not significantly higher following OGTT than IIGI, but was present in HC and CFnD. The calculated incretin effect was similar between HC and CFnD (28.2% and 29.1%) but significantly lower in CFRD vs. HC (-6.1% vs. 29.1%, p=0.03), (Figure 2).
Incretin hormones
Fasting total GLP-1 was significantly lower in the healthy controls compared to both the CFRD and CF groups (HC: 9.3 pmol/L vs. CFRD: 13.8 pmol/L, p<0.01; vs. CF: 13.7 pmol/L, p<0.01). There was no difference in fasting active GLP-1. Similarly, the AUC60OGTT for total GLP-1 was significantly higher in both the CF and CFRD groups than in healthy controls, but there was no difference in active GLP-1, (Table 3 & Figure 3). Fasting GIP was significantly higher in those with CFRD than healthy controls (55.6 pmol/L vs. 42.6 pmol/L, p<0.01), but not different between controls and the CFnD group. Similarly, although AUC60OGTT for GIP was significantly higher in the CFRD group than the healthy controls, there was no difference between controls and the CFnD group, (Table 3).
Discussion
In this study we investigated the incretin effect and incretin axis hormonal responses to oral and intravenous glucose challenges in people with CF. We found the incretin effect was lost in CFRD, where the insulin response to oral glucose was no different to that of intravenous glucose. 
In CF, although abnormal incretin hormone secretion has previously been reported,  ADDIN EN.CITE [12, 13] to date the incretin effect has not been directly studied. We performed oral glucose tolerance tests and matched isoglycaemic intravenous glucose infusions to evaluate the incretin effect in those with CFRD, CF without diabetes and matched healthy controls. The loss of the incretin effect was confirmed in those with CFRD where there was no increase in insulin secretion during OGTT relative to IIGI. Given the importance of post-prandial hyperglycaemia in CFRD, our results suggest that the loss of the incretin effect contributes to dysglycaemia and subsequent deleterious clinical outcomes in this population.
Although an impaired incretin effect is also a feature of other forms of diabetes, whether this is a causal factor or simply a consequence of the diabetic state is not clear.[14] The insulinotropic effects of GIP and to a lesser extent GLP-1 have been shown to be reduced in T2DM, suggesting that either reduced beta cell secretory capacity or a loss of beta cell sensitivity to incretin hormones may be responsible for the lack of incretin effect in T2DM.  ADDIN EN.CITE [15-17] Pharmacological manipulation of the incretin system has been associated with improved outcomes in type 2 diabetics and hence understanding whether these drugs may be useful in CFRD is of great interest.  ADDIN EN.CITE [8, 17, 18]
In CF, although relatively few studies have investigated the incretin hormones, the availability of licensed treatments targeting this axis has renewed interest. In our study, although the incretin effect was diminished in people with CFRD, there was no evidence of hyposecretion of either GLP-1 or GIP, in fact these hormones were hypersecreted compared to healthy controls. This indicates that it is a reduced insulinotropic, rather than reduced incretin hormone secretion, that is responsible for the loss of the incretin effect. Reduced insulinotropic effect of the incretin hormones could be explained by either reduced beta-cell secretory capacity of reduced incretin sensitivity. We did not directly assess either functions in this study, however, beta-cell mass and hence secretory capacity have previously been reported as reduced in CFRD  ADDIN EN.CITE [19-22] In keeping with this we found the post glucose C-peptide-glucose ratio, a surrogate of beta-cell area [23], was reduced in people with CFRD compared to healthy controls. 
As regards GIP, our finding of hypersecretion in CFRD is in keeping with other studies where higher fasting GIP and a larger response to OGTT were reported.  ADDIN EN.CITE [12, 24] Other studies which have reported normal or low GIP in CF did not differentiate between levels of dysglycaemia in their CF groups, or used mixed meals rather than a glucose challenge, potentially leading to different incretin axis stimulation.  ADDIN EN.CITE [25-29]
As regards GLP-1, we found similar fasting concentrations of active GLP-1 between all our study groups, confirming the findings of others. ADDIN EN.CITE [28-30] We also observed that all people with CF, (regardless of glycaemic status) had higher peak and initial total GLP-1 secretion than healthy controls but similar active GLP-1, indicating greater GLP-1 inactivation: this is in keeping with the only other study in CF measuring both active and total GLP-1. [31] GLP-1 is inactivated by DPP4, a serine protease which intriguingly can be upregulated in airway inflammation.  ADDIN EN.CITE [32] Increased airway inflammation associated with chronic suppurative lung infection is a hallmark of CF and an increase in circulating DPP4 could thus explain why those with CF, regardless of glycaemic state, require greater total GLP-1 secretion to achieve similar concentrations of active GLP-1 as healthy controls, this warrants further investigation.
Our findings have implications for the use of GLP-1 agonists in people with CF. The loss of incretin effect seen here makes modulation of that effect an attractive strategy to putatively reduce post-prandial hyperglycaemia. However, the hypersecretion of incretin hormones we found in people with CFRD may suggest beta-cells in a CFRD pancreas are no longer responsive to incretin hormones and the fact we found higher fasting GLP-1 concentration in people with CFRD suggests negative feedback mechanisms may have been lost. Nevertheless, supraphysiological incretin hormone doses may still be able to improve insulin secretion from beta-cells and studies including incretin hormone infusions are required to understand whether they may be of therapeutic benefit.   
The small sample size in this study is a limitation, and a larger sample size may have allowed us to also show statistically significant differences across the 120-240 minute time periods, however the study was adequately powered to detect differences in the incretin effect and also the changes in initial secretion of insulin and incretin hormones between those with CFRD and matched healthy controls. use of an oral glucose challenge rather than mixed meal may also have impacted our findings given incretin hormone stimulus varies between different types of meal. [33] However, we found evidence of hypersecretion of incretin hormones indicating that the incretin axis was adequately stimulated. Furthermore, in other forms of diabetes changes in incretin effects have been found to be consistent across a range of glucose loads.  ADDIN EN.CITE [34]





[1]	Nauck MA, Meier JJ (2016) The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 4(6): 525-536. 10.1016/S2213-8587(15)00482-9[2]	Moran A (2002) Endocrine complications of cystic fibrosis. Adolesc Med 13(1): 145-159, vii-viii[3]	Moran A, Becker D, Casella SJ, et al. (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 33(12): 2677-2683. 10.2337/dc10-1279[4]	Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ (2018) Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros 17(6): 798-803. 10.1016/j.jcf.2018.05.005[5]	Mannik LA, Chang KA, Annoh PQK, et al. (2018) Prevalence of hypoglycemia during oral glucose tolerance testing in adults with cystic fibrosis and risk of developing cystic fibrosis-related diabetes. J Cyst Fibros 17(4): 536-541. 10.1016/j.jcf.2018.03.009[6]	Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M (2011) Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care 34(4): e43. 10.2337/dc10-2286[7]	Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29(1): 46-52[8]	Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR (2010) Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 10: 20. 10.1186/1472-6823-10-20[9]	Green JB, Bethel MA, Armstrong PW, et al. (2015) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373(3): 232-242. 10.1056/NEJMoa1501352[10]	Hameed S, Morton JR, Jaffe A, et al. (2010) Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 33(2): 221-226. 10.2337/dc09-1492[11]	Murakami M, Une N, Nishizawa M, Suzuki S, Ito H, Horiuchi T (2013) Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus 2(1): 20. 10.1186/2193-1801-2-20[12]	Geffner ME, Lippe BM, Kaplan SA, et al. (1984) Carbohydrate tolerance in cystic fibrosis is closely linked to pancreatic exocrine function. Pediatr Res 18(11): 1107-1111. 10.1203/00006450-198411000-00011[13]	Ross SA, Brown JC, Dupre J (1977) Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26(6): 525-529[14]	Meier JJ, Nauck MA (2010) Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 59(5): 1117-1125. 10.2337/db09-1899[15]	Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA (2001) Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50(11): 2497-2504[16]	Vilsboll T, Knop FK, Krarup T, et al. (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88(10): 4897-4903. 10.1210/jc.2003-030738[17]	Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52(2): 380-386[18]	Clar C, Barnard K, Cummins E, Royle P, Waugh N, Aberdeen Health Technology Assessment G (2010) Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 14(12): 1-140. 10.3310/hta14120[19]	Handwerger S, Roth J, Gorden P, Di Sant' Agnese P, Carpenter DF, Peter G (1969) Glucose intolerance in cystic fibrosis. N Engl J Med 281(9): 451-461. 10.1056/NEJM196908282810901[20]	Barrio R (2015) Management of endocrine disease: Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues. Eur J Endocrinol 172(4): R131-141. 10.1530/EJE-14-0644[21]	Iannucci A, Mukai K, Johnson D, Burke B (1984) Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol 15(3): 278-284[22]	Sheikh S, Gudipaty L, De Leon DD, et al. (2017) Reduced beta-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes 66(1): 134-144. 10.2337/db16-0394[23]	Meier JJ, Menge BA, Breuer TG, et al. (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58(7): 1595-1603. 10.2337/db08-1611[24]	Ross SA, Morrison D, McArthur RG (1981) Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics 67(2): 252-254[25]	Perano SJ, Couper JJ, Horowitz M, et al. (2014) Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab 99(7): 2486-2493. 10.1210/jc.2013-4417[26]	Allen JM, Penketh AR, Adrian TE, et al. (1983) Adult cystic fibrosis: postprandial response of gut regulatory peptides. Gastroenterology 85(6): 1379-1383[27]	Adrian TE, McKiernan J, Johnstone DI, et al. (1980) Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 79(3): 460-465[28]	Lanng S, Thorsteinsson B, Roder ME, et al. (1993) Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh) 128(3): 207-214[29]	Ratkiewicz M, Pastore M, McCoy KS, Thompson R, Hayes D, Jr., Sheikh SI (2017) Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis. World J Pediatr 13(2): 129-135. 10.1007/s12519-017-0015-8[30]	Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J (2011) Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res 43(5): 355-360. 10.1055/s-0031-1275270[31]	Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M (2012) Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 11(2): 144-149. 10.1016/j.jcf.2011.11.001[32]	Shiobara T, Chibana K, Watanabe T, et al. (2016) Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res 17: 28. 10.1186/s12931-016-0342-7[33]	Vollmer K, Holst JJ, Baller B, et al. (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57(3): 678-687. 10.2337/db07-1124[34]	Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T (2011) Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96(3): 737-745. 10.1210/jc.2010-2435
[2]	Moran A (2002) Endocrine complications of cystic fibrosis. Adolesc Med 13(1): 145-159, vii-viii
[3]	Moran A, Becker D, Casella SJ, et al. (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 33(12): 2677-2683. 10.2337/dc10-1279
[4]	Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ (2018) Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros 17(6): 798-803. 10.1016/j.jcf.2018.05.005
[5]	Mannik LA, Chang KA, Annoh PQK, et al. (2018) Prevalence of hypoglycemia during oral glucose tolerance testing in adults with cystic fibrosis and risk of developing cystic fibrosis-related diabetes. J Cyst Fibros 17(4): 536-541. 10.1016/j.jcf.2018.03.009
[6]	Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M (2011) Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care 34(4): e43. 10.2337/dc10-2286
[7]	Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29(1): 46-52
[8]	Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR (2010) Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 10: 20. 10.1186/1472-6823-10-20
[9]	Green JB, Bethel MA, Armstrong PW, et al. (2015) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373(3): 232-242. 10.1056/NEJMoa1501352
[10]	Hameed S, Morton JR, Jaffe A, et al. (2010) Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 33(2): 221-226. 10.2337/dc09-1492
[11]	Murakami M, Une N, Nishizawa M, Suzuki S, Ito H, Horiuchi T (2013) Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus 2(1): 20. 10.1186/2193-1801-2-20
[12]	Geffner ME, Lippe BM, Kaplan SA, et al. (1984) Carbohydrate tolerance in cystic fibrosis is closely linked to pancreatic exocrine function. Pediatr Res 18(11): 1107-1111. 10.1203/00006450-198411000-00011
[13]	Ross SA, Brown JC, Dupre J (1977) Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26(6): 525-529
[14]	Meier JJ, Nauck MA (2010) Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 59(5): 1117-1125. 10.2337/db09-1899
[15]	Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA (2001) Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50(11): 2497-2504
[16]	Vilsboll T, Knop FK, Krarup T, et al. (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88(10): 4897-4903. 10.1210/jc.2003-030738
[17]	Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52(2): 380-386
[18]	Clar C, Barnard K, Cummins E, Royle P, Waugh N, Aberdeen Health Technology Assessment G (2010) Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 14(12): 1-140. 10.3310/hta14120
[19]	Handwerger S, Roth J, Gorden P, Di Sant' Agnese P, Carpenter DF, Peter G (1969) Glucose intolerance in cystic fibrosis. N Engl J Med 281(9): 451-461. 10.1056/NEJM196908282810901
[20]	Barrio R (2015) Management of endocrine disease: Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues. Eur J Endocrinol 172(4): R131-141. 10.1530/EJE-14-0644
[21]	Iannucci A, Mukai K, Johnson D, Burke B (1984) Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol 15(3): 278-284
[22]	Sheikh S, Gudipaty L, De Leon DD, et al. (2017) Reduced beta-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes 66(1): 134-144. 10.2337/db16-0394
[23]	Meier JJ, Menge BA, Breuer TG, et al. (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58(7): 1595-1603. 10.2337/db08-1611
[24]	Ross SA, Morrison D, McArthur RG (1981) Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics 67(2): 252-254
[25]	Perano SJ, Couper JJ, Horowitz M, et al. (2014) Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab 99(7): 2486-2493. 10.1210/jc.2013-4417
[26]	Allen JM, Penketh AR, Adrian TE, et al. (1983) Adult cystic fibrosis: postprandial response of gut regulatory peptides. Gastroenterology 85(6): 1379-1383
[27]	Adrian TE, McKiernan J, Johnstone DI, et al. (1980) Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 79(3): 460-465
[28]	Lanng S, Thorsteinsson B, Roder ME, et al. (1993) Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh) 128(3): 207-214
[29]	Ratkiewicz M, Pastore M, McCoy KS, Thompson R, Hayes D, Jr., Sheikh SI (2017) Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis. World J Pediatr 13(2): 129-135. 10.1007/s12519-017-0015-8
[30]	Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J (2011) Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res 43(5): 355-360. 10.1055/s-0031-1275270
[31]	Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M (2012) Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 11(2): 144-149. 10.1016/j.jcf.2011.11.001
[32]	Shiobara T, Chibana K, Watanabe T, et al. (2016) Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res 17: 28. 10.1186/s12931-016-0342-7
[33]	Vollmer K, Holst JJ, Baller B, et al. (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57(3): 678-687. 10.2337/db07-1124





Table 1: Clinical and metabolic characteristics of the three study groups (Control, CFRD and CF). 
Data are presented as count (%), mean (SD) or median [IQR]. Unadjusted p-values are presented throughout.  
 	HC	CFnD	CFRD	p
n	6	6	5	 
Age, years	28.0 [25.9, 29.0]	28.23 [26.8, 29.4]	27.1 [27.1, 36.9]	0.89
Sex, male	2 ( 33.3) 	5 ( 83.3)	5 (100.0)	0.038
Pancreatic enzymes	0 (0.0) 	6 (100.0)	5 (100.0)	<0.001
Height,cm	168.25 [164.75, 171.38]	175.7 [170.8, 179.6]	176.00 [167.6, 178.0]	0.62
Weight, kg	62.2 [59.2, 64.7]	64.6 [63.6, 71.0]	63.1 [60.2, 69.0]	0.44
BMI, kg/m2	22.0 [21.2, 22.6]	23.4 [20.8, 25.6]	23.4 [20.0, 24.4]	0.87
FEV1, litres	n/a	3.3 [2.7, 3.7]	2.5 [1.8, 2.7]	0.05
FEV1, % predicted	n/a	77.0 [64.3, 84.5]	55.0 [41.0, 64.0]	0.07
OGTT, mmol/L				
1-hr glucose	7.0 (2.0)	10.4 (2.1)	12.1 (3.9)	0.38
2-hr glucose	3.9 (1.0)	5.9 (1.9)	8.8 (5.3)	0.07
Max	9.1 (1.4)	9.3 (1.7)	12.9 (1.9)	<0.001
CGM				
% Time above 8mmol/L	n/a	5.1 (4.5)	12.3 (6.3)	0.08
Fasting glucose, mmol/L	  4.4 (0.5)	4.4 (0.57)	5.2 (0.69)	0.101
Fasting insulin, µU/mL	  6.2 (5.1)	3.2 (1.51)	2.6 (0.58)	0.161
HOMA-B	 91.3 [75.3, 242.9]	110.0 [53.86, 121.21]	31.8 [31.4, 54.0]	0.076




Abbreviations: BMI=Body mass index; FEV1= Forced expiratory volume in one second; OGTT=Oral glucose tolerance test; CGM=Continuous glucose monitor; HOMA-IR=Homeostatic model assessment of insulin resistance; HOMA-B=Homeostatic model assessment of beta-cell function; HC=Healthy control; CFnD=Cystic fibrosis without diabetes; CFRD=Cystic fibrosis related diabetes


Table 2: Integrated insulin, glucose and c-peptide responses (over 60 minutes and 240 minutes) to oral glucose (50g) and isoglycaemic intravenous (IV) glucose in healthy controls (HC), CF without diabetes (CFnd) and CFRD. Values are expressed as mean (SD).  Differences between the three groups were tested by the one-wave analysis of variance test (ANOVA). Where significance differences existed pairwise comparisons were then performed. Units used throughout are insulin: µU/mL.min, Glucose: mmol/L.min and C-peptide: µU/mL.min.

 		HC	CFnD	CFRD	 	p	Pairwise Comparisons
	 	 	 	 		 	HC vs.  CF	CF vs.    CFRD	CFRD vs. HC
AUC 60									
Glucose 	IIGI	181.63 (25.17)	169.39 (19.66)	214.87 (33.3)		0.03	0.19	0.02	0.05
Insulin	IIGI	945.61 (463.78)	544.02 (223.04)	517.58 (267.54)		0.08			
C-peptide	IIGI	76.07 (39.44)	49.94 (14.59)	36.94 (24.89)		0.09			
AUC 240									
Glucose	IIGI	641.03 (48.36)	667.42 (71.32)	859.28 (207.59)		0.02	0.76	0.05	0.03
Insulin	IIGI	2188.61 (959.44)	2046.29 (895.69)	2092.11 (808.83)		0.96			
C-peptide	IIGI	214.76 (111.03)	270.28 (103.83)	245.20 (115.05)		0.69			
									
AUC 60									
Glucose	OGTT	184.53 (26.32)	171.67 (23.76)	213.42 (31.22)		0.06			
Insulin	OGTT	1397.21 (634.26)	838.17 (430.64)	669.52 (241.65)		0.05	0.05	0.78	0.02
C-peptide	OGTT	114.90 (51.60)	67.12 (30.05)	56.22 (9.92)		0.03	0.04	0.07	0.02
AUC 240									
Glucose	OGTT	653.89 (74.19)	649.40 (810.21)	821.65 (163.01)		0.03	0.46	0.03	0.04
Insulin	OGTT	3147.06 (1296.64)	2684.95 (1340.06)	1987.55 (482.50)		0.28			
C-peptide	OGTT	320.42 (111.82)	319.22 (98.11)	245.76 (54.64)	 	0.36	 	 	 
Abbreviations: OGTT=Oral glucose tolerance test; IIGI=Intravenous isoglycaemic glucose infusion. HC= Healthy controls; CFnD=Cystic fibrosis but no diabetes; CFRD=Cystic fibrosis related diabetes

 
Table 3: Integrated incretin hormone responses (over 60 minutes and 240 minutes) to oral glucose (50g OGTT) and isoglycaemic intravenous glucose infusion (IIGI) in healthy controls (HC), CF without diabetes (CFnd) and CFRD. 
Values are expressed as mean (SD).  Differences between the three groups were tested by the one-wave analysis of variance test (ANOVA). Where significance differences existed pairwise comparisons were then performed. Units used throughout are pmol/L.min 

 	 	HC	CFnD	CFRD	 	p	Pairwise Comparisons	
AUC 60					 	HC vs. CF	CF vs. CFRD	CFRD vs. HC	
Total GLP-1	IIGI	616.63 (210.88)	728.27 (137.70)	669.37 (332.81)		0.71				
Active GLP-1	IIGI 	199.76 (102.42)	177.94 (92.28)	161.12 (69.10)		0.81				
GIP	IIGI	2053.14 (663.54)	3511.50 (1467.16)	2792.39 (1704.13)		0.2				
AUC 240	IIGI									
Total GLP-1	IIGI	2126.17 (759.74)	2376.35 (294.96)	2840.28 (1720.90)		0.54				
Active GLP-1	IIGI	744.15 (356.46)	683.10 (284.97)	623.78 (281.19)		0.82				
GIP	IIGI	8295.23 (2022.07)	12873.84 (5490.13)	9986.51 (6007.06)		0.27				
AUC 60										
Total GLP-1	OGTT	694.97 (308.07)	1062.13 (213.98)	1070.44 (254.69)		0.04	0.02	0.48	0.03	
Active GLP-1	OGTT	274.40 (165.27)	330.84 (157.77)	275.18 (194.15)		0.82				
GIP	OGTT	8606.07 (3048.04)	10352.81 (2225.73)	15559.27 (4050.15)		0.007	0.14	0.33	0.007	
AUC 240										
Total GLP-1	OGTT	2596.76 (1055.55)	3433.75 (1055.55)	3115.95 (854.35)		0.44				
Active GLP-1	OGTT	893.88 (467.08)	1080.43 (496.56)	855.25 (530.22)		0.72				
GIP	OGTT	34690.95 (10005.05)	40388.43 (7814.39)	46765.13 (10762.84)	 	0.15	 	 	 	









Figure 1: Time course during OGTT (solid lines) and IIGI (dotted lines) for Glucose (mmol/L), Insulin (mU/mL) and C-peptide (ng/mL). Data are presented as mean +/- SEM. HC=Healthy controls; CFnD= CF with no diabetes; CFRD=CF related diabetes; OGTT= Oral glucose tolerance test. IIGI = Isoglycaemic intravenous glucose infusion.















Figure 3: Time course during OGTT (solid lines & circles) and IGI (dotted lines & triangles) for Active GLP-1, Total GLP-1 and GIP. Data are presented as mean +/- SEM.
GIP=Gastric inhibitory polypeptide, pmol/L GLP-1=Glucagon like peptide-1, pmol/L; HC=Healthy controls; CFnD= CF with no diabetes; CFRD=CF related diabetes; OGTT= Oral glucose tolerance test. IIGI = Isoglycaemic intravenous glucose infusion.
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